Massachusetts healthcare cost growth beat its benchmark, but commission says drug prices are still a concern

Prescription Drugs and Money image
Although Massachusetts' healthcare growth rate was slower than the national average, economists are still concerned about drug prices. (TaxRebate.org.uk)

For the seventh year in a row, the growth of medical spending in Massachusetts was slower than in the rest of the country.

Massachusetts’ total healthcare costs grew 2.8% in 2016, below the national growth rate of 3.5%, according to the Massachusetts Health Policy Commission (HPC). State healthcare spending also fell below the 3.6% benchmark set by the HPC, an independent state agency.

The HPC monitors key healthcare cost drivers and found that prescription drugs and hospital outpatient departments were the biggest drivers of Massachusetts healthcare spending in 2016, growing 6.1% and 5.5%, respectively, according to the HPC report (PDF).

Free Daily Newsletter

Like this story? Subscribe to FierceHealthcare!

The healthcare sector remains in flux as policy, regulation, technology and trends shape the market. FierceHealthcare subscribers rely on our suite of newsletters as their must-read source for the latest news, analysis and data impacting their world. Sign up today to get healthcare news and updates delivered to your inbox and read on the go.

"While health care spending overall in Massachusetts was below the 3.6% benchmark and national trends, continued challenges, including high hospital outpatient spending and avoidable hospital use, remain,” Stuart H. Altman, Ph.D., HPC Board Chair and health economist, said in a release, highlighting ongoing affordability concerns for patients and employers. 

“The recommendations we make in the report—especially around enhancing transparency of pharmaceutical price growth, protecting consumers from outrageous out-of-network bills, and emphasizing the importance of social determinants of health—are critical to curbing this trend and ensuring the system works for everybody,” he added

RELATED: Industry Voices—Hospitals, middlemen inflating healthcare costs

The impact of prescription drug costs isn't limited to Massachusetts. A recent report released by Sen. Claire McCaskill, D-Mo., showed the prices of some brand-name drugs have soared since 2012. As policymakers gear up to address rising drug prices, the issue has been and remains a top concern for healthcare leaders.

To address leading cost drivers, HPC recommended that Massachusetts increase transparency and accountability in drug pricing to determine whether prices are excessive and unjustified, and to enhance the state's negotiating authority. It also calls on Massachusetts to equalize payments for services delivered at hospital outpatient departments and physician offices.

RELATED: The key drivers behind U.S. healthcare spending may surprise you

The HPC outlined several opportunities to improve the quality and efficiency of care delivered to the people of Massachusetts that could save $4.7 billion by 2022. The cost-savings targets include:

  • Reduce hospital readmissions by 20%.
  • Reduce institutional postacute care discharges by 25%.
  • Reduce available emergency department visits by 66%.
  • Shift 25% of community appropriate discharges from teaching hospitals to community hospitals.
  • Implement site-neutral outpatient reimbursement for certain conditions.
  • Limit the growth of prescription drug prices to 1.6%.
  • Expand the use of alternative payment methods.

Suggested Articles

President Donald Trump touted the administration’s expansion of HRAs, saying for many consumers HRAs “will be the way of the future.” 

State and federal officials said IBM will pay $14.8 million to settle allegations that it violated the False Claims Act.

A Pennsylvania appeals court has ruled that the government-brokered deal between UPMC and Highmark will end as scheduled on June 30.